Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | FABP3 | P05413 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851263 | 0.84 | CA12 (0.52) | ALDH1A1TSHRKMT2AMEN1CA12 | |
| SCHEMBL80183 | 0.84 | ALDH1A1 (0.64) | ALDH1A1DPP4PBRM1TSHRFEN1 | |
| SCHEMBL15616798 | 0.83 | ALDH1A1 (0.71) | ALDH1A1PBRM1TSHRFEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8042412 | 0.81 | ALDH1A1 (0.61) | ALDH1A1DPP4PBRM1TSHRFEN1 | |
| SCHEMBL1041643 | 0.81 | ALDH1A1 (0.61) | ALDH1A1DPP4PBRM1TSHRFEN1 | |
| SCHEMBL7425018 | 0.81 | ALDH1A1 (0.61) | ALDH1A1DPP4PBRM1TSHRFEN1 | |
| SCHEMBL15540940 | 0.81 | ALDH1A1 (0.50) | ALDH1A1PBRM1TSHRFEN1KMT2A | |
| SCHEMBL23908712 | 0.79 | ALDH1A1 (0.58) | ALDH1A1DPP4PBRM1TSHRFEN1 | |
| SCHEMBL19418807 | 0.76 | CA12 (0.52) | ALDH1A1TSHRFEN1KMT2AMEN1 | |
| SCHEMBL10415716 | 0.76 | CA12 (0.70) | ALDH1A1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114181076-A | Preparation method of 2, 6-dihalogenated methyl benzoate | 维思普新材料（苏州）有限公司 | 2022-03-15 | — | — | CN | claimed |
| US-20250360234-A1 | RADIOLABELLED MGL PET LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-27 | — | — | US | disclosed |
| US-12383635-B2 | Radiolabelled MGL PET ligands | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-12 | — | — | US | disclosed |
| EP-4038070-B1 | RADIOLABELLED MGL PET LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-09 | — | — | EP | disclosed |
| CN-114555596-B | Radiolabelled MGL PET ligands | 詹森药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-118373804-A | Preparation method of dihydrodibenzothiazepine derivative | 博骥源（上海）生物医药有限公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20240100198-A1 | RADIOLABELLED MGL PET LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-28 | — | — | US | disclosed |
| US-11839663-B2 | Radiolabelled MGL pet ligands | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-12 | — | — | US | disclosed |
| EP-4038070-A1 | RADIOLABELLED MGL PET LIGANDS | Janssen Pharmaceutica NV (BE) | 2022-08-10 | — | — | EP | disclosed |
| CN-114555596-A | Radiolabeled MGL PET ligands | 詹森药业有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |
| CN-103209695-A | Azabenzothiazole compounds, compositions and methods of use | HOFFMANN LA ROCHE | 2013-07-17 | — | — | CN | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| US-6949648-B2 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1270572-A1 | CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| CN-1268138-A | Compounds | ASTRA PHARMA PROD (GB) | 2000-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100198-A1 | RADIOLABELLED MGL PET LIGANDS | MGLL, LPL, LIPC | ALDH1A1 2498/4885DPP4 259/4885PBRM1 2886/4885 |
| US-11839663-B2 | Radiolabelled MGL pet ligands | MGLL, LPL, LIPC | ALDH1A1 2498/4885DPP4 259/4885PBRM1 2886/4885 |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | PTGS1, PTGIS, IL5 | ALDH1A1 1061/4885DPP4 684/4885PBRM1 3336/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | ALDH1A1 412/4885DPP4 1033/4885PBRM1 1563/4885 |
| US-12383635-B2 | Radiolabelled MGL PET ligands | MGLL, LPL, LIPC | ALDH1A1 2498/4885DPP4 259/4885PBRM1 2886/4885 |
| US-20250360234-A1 | RADIOLABELLED MGL PET LIGANDS | MGLL, LPL, LIPC | ALDH1A1 2486/4885DPP4 303/4885PBRM1 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.